Phase III IMpower 132 study + chemotherapy interim report for first line NSCLC. Genentech/Roche
Genentech, a member of the Roche Group announced results from the Phase III IMpower 132 study of Tecentriq (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). This interim analysis showed that Tecentriq and chemotherapy reduced the risk of disease worsening or death (progression-free survival, PFS) by 40 percent compared with chemotherapy alone (PFS=7.6 versus 5.2 months; hazard ratio [HR] = 0.60, 95 percent CI: 0.49-0.72; p<0.0001). while a numerical improvement of 4.5 months for the co-primary endpoint of overall survival (os) was observed, at this interim analysis statistical significance has not yet been met (median os="18.1" versus 13.6 months; hr="0.81," 95 percent ci: 0.64-1.03; p="0.0797)." the study will continue as planned, with final os results expected next year. safety for the tecentriq and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination.>
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins